European Journal of Clinical Pharmacology

, Volume 66, Issue 9, pp 871–877 | Cite as

CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking

  • Margareta Ramsjö
  • Eleni AklilluEmail author
  • Lilleba Bohman
  • Magnus Ingelman-Sundberg
  • Hyung-Keun Roh
  • Leif Bertilsson



To compare CYP2C19 enzyme activity between Swedes and Koreans controlling for the effect of CYP2C19 genotype, sex, oral contraceptive use, and smoking habits.


CYP2C19 activity was determined in 185 healthy Swedish and 150 Korean subjects as the omeprazole/5-hydroxyomeprazole ratio (metabolic ratio; MR) using high-performance liquid chromatography. Genotyping was performed by PCR using Taqman assay.


As expected, a higher incidence of poor metabolizers (PM) was found in Koreans (14%) compared with Swedes (3.8%) and the frequency of the CYP2C19*17 allele was very low in Koreans (0.3%). Among subjects homozygous for CYP2C19*1, Koreans displayed significantly lower CYP2C19 enzyme activity than Swedes (p < 0.000001). Interestingly, in Koreans a pronounced gender difference was apparent: females (n = 24) had significantly lower MR than males (n = 30; p < 0.0001), but such a gender difference was not seen among Swedes. Swedish OC users had a higher MR than non-users (p < 0.00001), whereas OC was only used by one Korean. No effects of smoking were observed.


We find specific gender-dependent effects of CYP2C19 activity in Koreans, but not in Swedes. Controlling for the effect of genotype and sex, Koreans display lower CYP2C19 activity than Swedes. The genetic, epigenetic or environmental basis for this difference remains to be identified.


CYP2C19 Omeprazole Gender Korean Swedes 



The study was financially supported by the Swedish Research Council, Medicine, 3902 and the Swedish Capio Forskningsstiftelse.


  1. 1.
    Brosen K (2004) Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 59(1):5–12CrossRefPubMedGoogle Scholar
  2. 2.
    Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45(4):348–355PubMedGoogle Scholar
  3. 3.
    Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism—a panel study. Br J Clin Pharmacol 31(6):689–692PubMedGoogle Scholar
  4. 4.
    Li XQ, Andersson TB, Ahlstrom M, Weidolf L (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32(8):821–827CrossRefPubMedGoogle Scholar
  5. 5.
    Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Meyer UA, Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36(6):521–530PubMedGoogle Scholar
  6. 6.
    Laine K, Tybring G, Bertilsson L (2000) No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 68(2):151–159CrossRefPubMedGoogle Scholar
  7. 7.
    Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5(6):358–363CrossRefPubMedGoogle Scholar
  8. 8.
    Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39(6):533–537CrossRefPubMedGoogle Scholar
  9. 9.
    Jurima M, Inaba T, Kadar D, Kalow W (1985) Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 19(4):483–487PubMedGoogle Scholar
  10. 10.
    Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38(4):402–408PubMedGoogle Scholar
  11. 11.
    Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, Liao CL, Zhang LM (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46(2):198–207PubMedGoogle Scholar
  12. 12.
    Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjoqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51(4):388–397PubMedGoogle Scholar
  13. 13.
    Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Andersson T, Regardh CG, Lou YC, Zhang Y et al (1994) Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 16(2):214–215CrossRefPubMedGoogle Scholar
  14. 14.
    Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L (1996) CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6(6):547–551CrossRefPubMedGoogle Scholar
  15. 15.
    De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269(22):15419–15422PubMedGoogle Scholar
  16. 16.
    De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46(4):594–598PubMedGoogle Scholar
  17. 17.
    Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103–113CrossRefPubMedGoogle Scholar
  18. 18.
    Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E (2004) The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 32(5):484–489CrossRefPubMedGoogle Scholar
  19. 19.
    Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E (2008) Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 64(4):381–385CrossRefPubMedGoogle Scholar
  20. 20.
    Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L (2007) Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63(6):537–546CrossRefPubMedGoogle Scholar
  21. 21.
    Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U, Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73(6):517–528CrossRefPubMedGoogle Scholar
  22. 22.
    Tybring G, Bottiger Y, Widen J, Bertilsson L (1997) Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 62(2):129–137CrossRefPubMedGoogle Scholar
  23. 23.
    Xie HG, Huang SL, Xu ZH, Xiao ZS, He N, Zhou HH (1997) Evidence for the effect of gender on activity of (S)-mephenytoin 4′-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics 7(2):115–119CrossRefPubMedGoogle Scholar
  24. 24.
    Gomez A, Ingelman-Sundberg M (2009) Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 85(4):426–430CrossRefPubMedGoogle Scholar
  25. 25.
    Kim JI, Ju YS, Park H, Kim S, Lee S, Yi JH, Mudge J, Miller NA, Hong D, Bell CJ, Kim HS, Chung IS, Lee WC, Lee JS, Seo SH, Yun JY, Woo HN, Lee H, Suh D, Kim HJ, Yavartanoo M, Kwak M, Zheng Y, Lee MK, Kim JY, Gokcumen O, Mills RE, Zaranek AW, Thakuria J, Wu X, Kim RW, Huntley JJ, Luo S, Schroth GP, Wu TD, Kim H, Yang KS, Park WY, Church GM, Lee C, Kingsmore SF, Seo JS (2009) A highly annotated whole-genome sequence of a Korean individual. Nature 460(7258):1011–1015PubMedGoogle Scholar
  26. 26.
    Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, de Zeeuw RA, Jonkman JH (1999) CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55(3):177–184CrossRefPubMedGoogle Scholar
  27. 27.
    Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51(2):169–173CrossRefPubMedGoogle Scholar
  28. 28.
    Palovaara S, Tybring G, Laine K (2003) The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol 56(2):232–237CrossRefPubMedGoogle Scholar
  29. 29.
    Suzuki T, Matsuo K, Sawaki A, Wakai K, Hirose K, Ito H, Saito T, Nakamura T, Yamao K, Hamajima N, Tajima K (2007) Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiol Infect 135(1):171–176CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Margareta Ramsjö
    • 1
  • Eleni Aklillu
    • 1
    Email author
  • Lilleba Bohman
    • 1
  • Magnus Ingelman-Sundberg
    • 2
  • Hyung-Keun Roh
    • 3
  • Leif Bertilsson
    • 1
  1. 1.Division of Clinical Pharmacology, Department of Laboratory Medicine at Karolinska InstitutetKarolinska University Hospital-Huddinge C1:68StockholmSweden
  2. 2.Section of Pharmacogenetics, Department of Pharmacology and PhysiologyKarolinska InstitutetStockholmSweden
  3. 3.Division of Clinical Pharmacology, Department of Internal MedicineGachon University HospitalIncheonKorea

Personalised recommendations